OVERVIEW

Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of Novel Therapies in AML is organized by Physicians' Education Resource, LLC (PER).

Release Date: August 30, 2019
Expiration Date: August 30, 2020

Target Audience:
This educational program is directed toward medical oncologists and hematologists interested in the treatment of AML. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with AML will be invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Activity Overview:
Recent years have marked a period of rapid growth in AML therapeutics, with several new medications approved in 2017 and 2018. In this innovative online program chaired by Naval G. Daver, MD, and joined by Harry P. Erba, MD, PhD; Amir T. Fathi, MD; and Tapan M. Kadia, MD, experts discuss best practices in implementing new therapies across lines of care. Understanding the mechanistic characteristics of novel targeted therapies and reformulated liposomal chemotherapy is crucial to optimizing care of patients with AML in 2019. Now more than ever, understanding the state of the art in risk stratification, treatment, efficacy data, and adverse event management in an era of constant change in AML has the potential to improve clinical outcomes for patients. This program is an opportunity to learn the crucial updates and hear expert perspectives directly from top faculty and trialists.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Identify latest best practices for testing strategies and risk stratification for patients with AML.
• Describe safety and efficacy data from the latest clinical trials with recently approved and emerging treatment options across the continuum of care in AML.
• Integrate optimized treatment approaches for AML, including treatment strategies indicated for elderly patients with AML.
• Define strategies for proactive identification and management of treatment-related toxicities for patients with AML.

Additional details will be posted as soon as information is available.